Theriva Biologics, Inc.
TOVX
$0.25
$0.000.77%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 300.00K | 300.00K | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 300.00K | 300.00K | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 300.00K | 300.00K | -- | -- | -- |
| SG&A Expenses | 7.06M | 7.01M | 6.39M | 6.19M | 6.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.37M | 13.00M | 14.99M | 16.55M | 17.19M |
| Operating Income | -12.07M | -12.70M | -14.99M | -16.55M | -17.19M |
| Income Before Tax | -11.62M | -21.46M | -23.74M | -26.19M | -29.56M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.62 | -21.46 | -23.74 | -26.19 | -29.56 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.62M | -21.46M | -23.74M | -26.19M | -29.56M |
| EBIT | -12.07M | -12.70M | -14.99M | -16.55M | -17.19M |
| EBITDA | -11.96M | -12.60M | -14.89M | -16.44M | -17.08M |
| EPS Basic | -0.69 | -2.55 | -4.06 | -5.53 | -11.89 |
| Normalized Basic EPS | -0.37 | -0.69 | -1.63 | -2.52 | -4.64 |
| EPS Diluted | -0.69 | -2.55 | -4.06 | -5.53 | -11.89 |
| Normalized Diluted EPS | -0.37 | -0.69 | -1.63 | -2.52 | -4.64 |
| Average Basic Shares Outstanding | 125.92M | 86.78M | 48.49M | 22.00M | 13.46M |
| Average Diluted Shares Outstanding | 125.92M | 86.78M | 48.49M | 22.00M | 13.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |